| Literature DB >> 27612594 |
Paulo Mendes Peçanha1, Stella de Souza1, Aloísio Falqueto1, Tânia Regina Grão-Veloso1, Ludmila Ventura Lírio1, Carlos Urbano Gonçalves Ferreira1, Aline Rocha Santos1, Hélbia Garcia Costa1, Lúcia Renata Meirelles de Souza1, Felipe Francisco Tuon2.
Abstract
Amphotericin B deoxycholate is the main option for intravenous (i.v.) treatment of severe paracoccidioidomycosis (PCM). This is the first report of amphotericin B lipid complex (ABLC) in the treatment of PCM. Among 28 patients, cure was achieved in all patients (100%) using ABLC. Mean and median daily doses of ABLC were 3.39 mg/kg/day and 3.35 mg/kg/day, respectively. ABLC may be a choice in the treatment of severe forms of PCM or when i.v. options are required.Entities:
Keywords: Amphotericin B; Amphotericin B lipid complex; Liposomal amphotericin B; Paracoccidioides brasiliensis; Paracoccidioidomycosis
Mesh：
Substances：
Year: 2016 PMID： 27612594 DOI： 10.1016/j.ijantimicag.2016.06.011
Source DB: PubMed Journal: Int J Antimicrob Agents ISSN： 0924-8579 Impact factor: 5.283